<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review Nature publication of promising pre-clinical results for second-generation COVID-19 vaccine candidate, CV2CoV, in study with Harvard Medical School, showing comparable immune response to a licensed mRNA vaccine Positive developments across rest of the pipeline, including pre-clinical results in molecular therapies and progress of Phase 1 study with lead candidate in oncology Re-allocation of existing manufacturing lines and capacities to support second-generation program and streamlining of external manufacturing network Cash position of €1.06 billion as of September 30, 2021. CureVac continues to assess supplier commitments related to the withdrawal of first-generation COVID-19 vaccine candidate CureVac will host a webcast and conference call on Friday, November 19, 2021, at 8 a.m.
...read full article on Accesswire
